Company Overview and News

 
Hazer Group independent testing validates technology

2018-09-18 proactiveinvestors.com.au
Hazer Group Ltd (ASX:HZR) has had its proprietary Hazer Process successfully tested and validated in an independently designed and operated external Fluidized Bed Reactor (FBR).
HZR

6
RIU GoodOilConference Perth attracts oil and gas plays on the hunt for juniors

2018-09-11 proactiveinvestors.com.au
RIU GoodOilConference Perth kicks off tomorrow morning in East Perth, with a number of large and medium-sized companies attending to see what junior companies will be up to in the coming year.
PCL CVN HZN TAO SRNLY SUR LIO TAOIF OGFGY COP HZNFF BEPTF LIOEF COMRF CPTLY SHI WBC COI SNP STO ADXRF WEBNF WBK ADX BCHEY CVONF BPT RLE WBC CTP WEL HZR OGFGF ORG

6
RIU GoodOilConference Perth to start with market update from Argonaut director Michael Eidne

2018-09-11 proactiveinvestors.com.au
RIU GoodOilConference Perth kicks off tomorrow morning in East Perth, with Argonaut research director Michael Eidne delivering the low-down on the current state of the industry in his opening address.
PCL CVN HZN TAO SRNLY SUR LIO TAOIF OGFGY COP HZNFF BEPTF LIOEF COMRF CPTLY SHI WBC COI SNP STO ADXRF WEBNF WBK ADX BCHEY CVONF BPT RLE WBC CTP WEL HZR OGFGF ORG

 
RIU GoodOilConference Perth and WA Petroleum Day to put oil and gas players centre stage

2018-09-07 proactiveinvestors.com.au
The RIU GoodOilConference in Perth next week will focus on the current state of the oil and gas industry, and the explorers and producers operating in Australia.
FAR TEG HZN SXA SGC SRNLY LIO TAOIF BAS ICN BEPTF MUR COMRF CPTLY COPJF AGYYF NWE STRXD STRXF CUE ADX CTP EXR HZR BRU PCL CVN TAO SUR MEL LCK HZNFF ROG LIOEF BRNGF ICNOF FARYF COE CUEYF COI ADXRF ELXPF BCHEY CVONF CUEYY BPT AJQ RLE OIEXF CVX KEY OEX

 
Board moves; Ward, Minosora

2018-08-30 businessnews.com.au
Perth-based Geoff Ward has been appointed as chief executive of local tech company Hazer Group, while Michael Minosora is set to chair junior explorer Golden Deeps.
HZR

 
Hazer Group to move pilot plant to Mineral Resources site

2018-08-29 proactiveinvestors.com.au
Hazer Group Ltd (ASX:HZR) plans to relocate its fluid bed reactor (FBR) pilot plant from Sydney to Mineral Resources Ltd’s (ASX:MIN) Perth site.
MALRY HZR MALRF MIN

 
Hazer Group commissions studies for plants aimed at building business case for Hazer process

2018-08-22 proactiveinvestors.com.au
Hazer Group Ltd (ASX:HZR) has commissioned engineering studies for a small demonstration plant and a commercial plant aimed at building a business case for the Hazer low-emission hydrogen and graphite production process.
HZR

 
Hazer Group pre-pilot plant now considered a pilot plant, as tests beat targets by 300%

2018-08-22 proactiveinvestors.com.au
Hazer Group Ltd (ASX:HZR) chief technical officer Andrew Cornejo speaks to Proactive Investors about recent pilot plant testing results that beat capacity targets by 300%.
HZR

 
Hazer Group shares rise on pilot plant results

2018-08-10 proactiveinvestors.com.au
Hazer Group Ltd (ASX:HZR) has exceeded capacity targets by 300% in its successfully upgraded and commissioned 2nd generation pre-pilot plant, also known as the FBR pilot plant.
HZR

 
Hazer Group share rise on pilot plant results

2018-08-09 proactiveinvestors.com.au
Hazer Group Ltd (ASX:HZR) has exceeded capacity targets by 300% in its successfully upgraded and commissioned 2nd generation pre-pilot plant, also known as the FBR pilot plant.
HZR

 
Hazer looking to scale proprietary process to create clean hydrogen and graphite

2018-07-19 proactiveinvestors.com.au
Hazer Group Ltd (ASX:HZR) chief technical officer Andrew Cornejo speaks to Proactive Investors about the company's proprietary process for creating low emission hydrogen and graphite.
HZR

 
Hazer Group shares surge following significant performance improvements for its unique process

2018-07-19 proactiveinvestors.com.au
Hazer Group Ltd (ASX:HZR) has demonstrated a 400% increase in the average production rate of hydrogen and graphite during final test runs on its 1st generation pre-pilot plant (PPP).
HZR

 
Hazer Group demonstrates proof of concept to produce graphite and hydrogen

2018-06-27 proactiveinvestors.com.au
Hazer Group Ltd (ASX:HZR) has opened a potential pathway to commercialise its Hazer Process, following a proof of concept demonstration using an alternate reactor demonstrated the flexibility of the company's technology.
HZR

4
Hazer Group commences pilot plant development with Mineral Resources

2018-06-06 proactiveinvestors.com.au
Hazer Group Ltd (ASX:HZR) has commenced the joint development of the Mineral Resources Ltd (ASX:MIN) pilot plant which is on track to be commissioned in the September quarter of 2018.
MALRY HZR MALRF MIN

4
Hazer posts battery-ready performance from graphite testing

2018-05-10 australianmining.com.au
Perth-based graphite company Hazer Group, which made waves late last year following a high-profile, clean fuel production deal with Mineral Resources, has announced positive test results from recovered graphite samples.
MALRY HZR MALRF MIN

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...